Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 19 October

Jessica Amir
October 19, 2021

Morning Bell 18 October

Jessica Amir
October 18, 2021

Weekly Wrap 15 October

Jessica Amir
October 15, 2021

Morning Bell 15 October

Paulina Peters
October 15, 2021

Morning Bell 14 October

Jessica Amir
October 14, 2021

Morning Bell 13 October

Jessica Amir
October 13, 2021

Morning Bell 12 October

Sophia Mavridis
October 12, 2021

Morning Bell 11 October

Jessica Amir
October 11, 2021

Weekly Wrap 8 October

Jessica Amir
October 8, 2021

Morning Bell 8 October

Paulina Peters
October 8, 2021

Morning Bell 7 October

Jessica Amir
October 7, 2021

Morning Bell 6 October

Jessica Amir
October 6, 2021